Carmat SA (ALCAR.PA) Key Developments |
United States

Analyst Research

Report Title Price
Provider : Reuters Investment Profile
Provider : GlobalData
Provider : Edison Investment Research
Provider : GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Carmat to resume first-in-man trial with its bioprosthetic heart

Wednesday, 16 Jul 2014 02:00pm EDT 

Carmat SA:Obtains approval to resume first-in-man trial with its bioprosthetic heart.Patient enrollment put on hold in March to allow data from first implanted prosthesis to be analyzed.Favorable opinion regarding resumption of enrollment of next three patients given by ethics committee, data and safety monitoring board and regulatory authorities. 

Company Quote

-0.73 -2.65%
1 Jul 2016